EGLN1 and cancer: Jiang et al. [28] demonstrated a molecular basis for the Egl Nine Homolog 1 (EGLN1)/c-Myc-mediated induction of the LSH expression that inhibits ferroptosis, and this discovery can be applied to develop therapeutic strategies targeting ferroptosis in the cancer therapy.